Tag Archives: Lubrizol

Lubrizol Opens State-of-the-Art Drumming Facility

(BRK.A), (BRK.B)

The Lubrizol Corporation has opened a state-of-the-art drumming facility and warehouse at its Painesville Township, Ohio manufacturing facility, both of which are part of the company’s previously announced phased investment at the site.

The total $70 million investment better positions the company to meet the changing demands of customers and ensures the integrity and quality of its products while reinforcing personal and environmental safety.

Construction on the 180,000 square feet combined buildings began in April 2015. With a focus on enhancing safety and business processes, the new buildings will be instrumental in reducing risk and achieving the company’s business objectives of improving effectiveness, efficiency and consistency.

“Historically, the Painesville Township site has been of great importance to our business, operating for more than 60 of the company’s nearly 90 years,” said Tom Curtis, incoming president of Lubrizol Additives. “This latest investment reinforces our commitment to the community by further ensuring the site as a key source in Lubrizol Additives’ global supply chain.”

With more than half of all Lubrizol Additives products worldwide containing at least one component manufactured at the Painesville Township site, adding new manufacturing capacity and updated automated packaging capabilities was a necessity. Furthermore, these efforts are important to ensure product integrity and to improve the overall safety and efficiency of handling product drums and totes.

“With our new drum filling facility, we will be able to improve safety by minimizing the manual packaging of drums, reducing packaging time for a single batch by more than 50% and minimizing the number of times a drum is handled by more than 70%,” commented Craig Hupp, Lubrizol Painesville Township plant manager. “And, with 100% indoor storage provided by our new warehouse, we will improve the quality and appearance of packaged products delivered to our customers. All of these improvements will be a tremendous value to our overall organization.”

© 2017 David Mazor

Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.

Lubrizol’s LifeSciences Investing $10 Million at Wisconsin Manufacturing Site

(BRK.A), (BRK.B)

The Lubrizol Corporation’s LifeSciences business is investing $10 million for a significant capacity expansion at its silicone contract manufacturing site in Franklin, Wisconsin.

This investment strengthens the company’s silicone business by adding 71,000 square feet of space that complements the existing 126,000 square foot operation.

Previously, in 2010, Vesta more than doubled its footprint at this location; the current expansion supports LifeSciences’ long-term growth strategy to provide high-quality manufacturing for silicone implants and finished medical devices.

“When customers partner with Lubrizol LifeSciences, they benefit from working with us at every stage in their development process,” states Uwe Winzen, general manager, Lubrizol LifeSciences. “With a long history of polymer expertise combined with recent investments, Lubrizol LifeSciences is positioned to offer full-service development for the next generation of medical devices, as well as long-term implantable and drug-eluting device innovations.”

The expansion adds 71,000 square feet of new space featuring product development, cellular manufacturing, and high-efficiency production lines, as well as separate Class 7 & 8 clean room space for the production of implants and drug-eluting devices.

The expansion allows LifeSciences to capitalize on the strong local labor pool and technical expertise offered in the Wisconsin area.

“This new space covers immediate short-term needs, but also provides room for growth in the future. Customers can feel comfortable that we are able to handle both their current projects, as well as a significant increase in their future business efforts,” states Mark Stuart, general manager, Vesta. “Companies looking for a world-class, efficient contract manufacturing partner can choose us knowing that we are a sustainable partner for their long term growth.”

© 2017 David Mazor

Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.

Lubrizol Upgrades Textile Coatings Center of Excellence

(BRK.A), (BRK.B)

What’s more excellent than excellent? Excellenter? Excellentest? Well, anyway, Berkshire Hathaway’s Lubrizol has announced that its Performance Coatings business is upgrading its Textile Coatings Center of Excellence in Gastonia, North Carolina.

The facility, which focuses on research and development of coatings technologies for textile and non-woven substrates, and is dedicated to formulating and testing innovative coating technologies for an array of technical textile applications.

The new Center of Excellence is a state of the art textile coating product development and applications testing facility.

“By upgrading our capabilities, we continue our longstanding commitment to the textiles industry”, says Bob Bonner, technical manager. “This investment expands our ability to deliver a wide range of textile coating and testing services for customers, including flame retardancy, abrasion resistance, water repellency, chemical resistance, and stretch-restriction capability.”

“Our textiles team in Gastonia is focused on providing an outstanding experience for customers through technical service”, comments Ted Parigian, sales manager, textile coatings. “They’re constantly developing new technologies, and these upgrades will enhance our ongoing ability to deliver winning solutions.”

Lubrizol investments in global Center of Excellences ensure the ability for highly skilled technical experts to collaborate with customers and each other in world class labs with modern equipment to efficiently deliver advanced coating technologies to customers. “Reducing our response time to customers is a key business goal,” notes Lee Young, technical director. “When we can bring the right, differentiated products to customers and meet their time requirements in the process, then we are a critical part of their success and profitability.”

© 2017 David Mazor

Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.

Particle Science to Begin Commercial Drug Manufacturing

(BRK.A), (BRK.B)

Commercial drug product manufacturing will be added at the Lubrizol’s Particle Sciences facility in Bethlehem, Pennsylvania.

The move to become a commercial drug product manufacturer, rather than just a producer of trial supplies used in testing, will enable Particle Science to produce pharmaceutical products for commercial sale by its customers.

Particle Science already has several customers lined up for its new service, and plans to hire an additional 30 employees to its existing workforce of 85 employees.

The roughly $10 million expansion of its facility will be adjacent to the existing development and clinical trial manufacturing site, offering customers a seamless flow from development through manufacturing.

The new space, which is expected to be operational in the fourth quarter of 2017, will accommodate both sterile and non-sterile products, highly potent compounds, and organic solvent processing.

The expansion id part of Lubrizol’s $60 million investment that will focus on new product solutions, capacity expansion and additional cGMP manufacturing.

© 2017 David Mazor

Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.

Lubrizol Investing $60 Million to Expand Particle Sciences, Vesta and Other Facilities in 2017

(BRK.A), (BRK.B)

The Lubrizol Corporation’s LifeSciences business is continuing to invest in its key capabilities through a variety of planned expansions.

During this latest phase, a $60 million investment will focus on new product solutions, capacity expansion and additional cGMP manufacturing. These investments will strengthen the excipients, polymers, drug formulation and manufacturing, and medical device contract manufacturing capabilities at Lubrizol LifeSciences’ global facilities.

Commercial drug product manufacturing will be added at the company’s Particle Sciences facility in Bethlehem, PA. Leveraging the company’s knowledge in complex formulations and production, the facility will be adjacent to the existing development and clinical trial manufacturing site, offering customers a seamless flow from development through manufacturing. This new space, which is expected to be operational in the fourth quarter of 2017, will accommodate both sterile and non-sterile products, highly potent compounds, and organic solvent processing.

Additionally, LifeSciences is investing to expand its global facilities for excipients, polymers and contract manufacturing, with a focus on quality and efficiency. This capital investment will impact multiple sites to increase in-house engineering capacity across the LifeSciences portfolio of medical and pharmaceutical applications. This includes new investments in design, manufacturing and sterilization technologies for the production of interventional catheters and long-term implantable devices, an area of strategic importance to the medical device segment.

“We have significantly enhanced our capabilities through the combination of strong polymer technology, application know-how and world-class manufacturing,” states Deb Langer, vice president, Lubrizol Personal Home and Health Care.

“As healthcare companies look for total solution providers, we continue to invest in the right areas to provide valuable offerings where our customers are experiencing the most growth.”

© 2017 David Mazor

Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.

Warren Buffett Wishes For Five More Lubrizols

(BRK.A), (BRK.B)

If there is any one of Berkshire Hathaway’s companies that Warren Buffett would love to find another of it would have to be Lubrizol Corporation.

Berkshire acquired the specialty chemical manufacturer in 2011 for $9.7 billion, and it has played an important role in Berkshire’s profits.

“Lubrizol is the second largest in terms of earnings so it’s a very important asset to Berkshire,” Buffett noted during a recent visit to Lubrizol’s headquarters in Wickliffe, Ohio. “Up until the acquisition of Precision Cast Parts [it was] the largest industrial operation we have.”

Lubrizol’s growth, which since being acquired by Berkshire has included the acquisition of Particle Science, the opening of a chlorinated polyvinyl chloride (CPVC) compounding plant in Dahej, India, and assuming the Indian government’s stake in Lubrizol India Pvt Ltd., and more.

“It’s a terrific business and it’s big, and only gets bigger,” Buffet said.

With Berkshire size matters, as small acquisitions don’t make much difference in the profits of a company the size that Berkshire has grown to. Over the past decade, Berkshire has added not only Lubrizol, but also BNSF Railway, Precision Castparts, battery-maker Duracell, and a hefty chunk of Kraft Heinz to its portfolio.

While individual Berkshire companies can grow through smaller acquisitions in the millions, tens of millions, or even hundreds of millions, those size acquisitions don’t make sense for Berkshire if they are stand-alone entities. Berkshire has to add companies with billions in market cap in order to make a difference.

Companies of Lubrizol’s size are in the range that Buffett looks for with his famed “elephant gun.”

“It’s a huge advantage to be large too in terms of moving the needle on $400 billion of market cap.” Buffett noted, referring to Berkshire’s overall size.

Buffett’s a willing buyer, but companies such as Lubrizol are not on every corner.

“I wish we had five more and they’re hard, they are very hard to find,” Buffet said. “They take decades and decades to build.”

Buffett’s reputation as a long term owner of companies who keeps key management in place is one the things that makes becoming a Berkshire company attractive. The other is no longer having to be a slave to quarterly earnings reports. Just ask the folks at BNSF Railway how much easier it is to allocate capital now that they have been freed of that burden.

“We want Berkshire to be a wonderful collection of businesses over time, because we’re not going to sell them. It isn’t like we are going to keep culling the herd.”

If you can find Buffett another Lubrizol he’s certainly ready to thank you.

“Find me another Lubrizol, I’ll send flowers to your wife on her birthday,” Buffett adds. And he means it.

© 2017 David Mazor

Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.

Lubrizol Breaks Ground on Polyisobutylene Unit in Texas

(BRK.A), (BRK.B)

Berkshire Hathaway’s Lubrizol Corporation has broken ground on the construction of a new polyisobutylene (PIB) unit at its Deer Park, Texas facility.

The facility is being developed as part of Lubrizol’s previously announced technology license agreement with Daelim Industrial.

Commenting on the new unit, Dan Sheets, president of Lubrizol Additives, states “With this significant investment, Lubrizol intends to meet future customer demands, as well as be fully prepared for anticipated performance upgrades in lubricants and fuels.”

The new unit is expected to be fully operational in the first half of 2019. It will provide Lubrizol with capacity for highly reactive polyisobutylene (HR PIB), a key raw material for next-generation dispersants and lubricants.

© 2017 David Mazor

Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.

Lubrizol Buys Government’s 24% stake in India Joint Venture

(BRK.A), (BRK.B)

The state-run Indian Oil Corp has agreed to sell a 24 percent stake in a joint venture to the US-based partner Lubrizol Corporation.

The transaction will enable Lubrizol to take over the government’s stake in Lubrizol India Pvt Ltd, according to a government statement. When completed, Lubrizol’s ownership in the company will reach 74%.

The move comes as the Indian government plans to divest its interest in public companies.

“The sale will enable IOC to have long term association with its joint venture partner and … Lubrizol India Pvt Ltd (LIPL) to have access to the latest global additive technologies developed by Lubrizol Corporation, USA,” the statement said.

© 2017 David Mazor

Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.

Lubrizol Signs Agreement with Finolex Industries for CPVC Pipe in India

(BRK.A), (BRK.B)

Berkshire Hathaway’s Lubrizol Corporation, inventors and the largest manufacturers of CPVC compound worldwide, and Finolex Industries Limited, the leading PVC pipes and fittings manufacturer in India,have announce the signing of, FlowGuard® Processor agreement for the manufacturing and sale of Finolex FlowGuard®Plus pipes and fittings in India.

In August, 2016, Lubrizol terminated its processor agreements with Astral Poly-Technik Limited for the manufacture and sale of FlowGuard®, BlazeMaster® and Corzan® branded pipes and fittings in India.

Under the new agreement, Finolex Industries will begin marketing in the last week of March 2017, and will cater to the building and construction industry.

“Lubrizol is dedicated to supplying the highest quality CPVC compounds to service the Indian hot & cold water plumbing markets,” explains Matthew Timmons, managing director, Lubrizol Advanced Materials India Pvt. Ltd. “Our partnership with Finolex Industries highlights the need and importance of quality CPVC pipes and fittings made from time-tested CPVC compounds provided by Lubrizol. Since January 2016, we have been manufacturing these world quality materials from a state-of-the art plant in Dahej, Gujarat. Our association with Finolex will further strengthen FlowGuard’s commitment to delivering reliability in India through Finolex’s wide spread network in the country.”

Timmons continues, “Since we introduced FlowGuard to the Indian market, we remained committed through our support of processors who continue to benefit from our more than 50 years of expertise in manufacturing and compounding. Additionally, with the government’s recent focus on housing for all, the infrastructure status given to real estate, loans offered at cheaper rates, introduction of the Real Estate Regulatory Act (RERA), GST & many other initiatives, the need for quality products to be used in the country is greater than ever.”

Lubrizol introduced the resilient CPVC material into India nearly two decades ago. Since then, India’s plumbers, engineers, builders and consultants have been reassured by the only material of its kind to be designed and approved to meet all global standards.

Prakash Chhabria, executive chairman of Finolex Industries Limited expressed his views on the special occasion, saying, “We are committed to strengthening the plumbing industry through our association with Lubrizol falls in line with the culture of Finolex Industries in providing quality products ‘Made in India’ for the Indian market. We are confident about Lubrizol’s global expertise in compounding and appreciate the work done by them in changing the plumbing industry from metal-based to CPVC–based piping. With FlowGuard’s raw material and support, our track record of providing superior products for Indian market gets strengthened. We look forward to a successful partnership.”
industry and we are honored they have chosen to take advantage of our industry-leading cold chain network, expanded fresh foods program and award-winning category management expertise. We are proud to partner with such a strong leader within our industry and look forward to building the foundation for a long lasting and mutually successful relationship.”

© 2017 David Mazor

Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized

Lubrizol LifeSciences Announces New Compounding Capabilities

(BRK.A), (BRK.B)

The Lubrizol Corporation’s LifeSciences (LLS) business has announced the addition of compounding capabilities for its Pellethane® and Isoplast® products for medical device customers.

The new offering enables LLS to provide color matching, radiopacity and custom compound development services and complements LifeSciences’ existing polymer portfolio, formulation and manufacturing capabilities to enable success for medical device customers.

As part of this new service, LLS provides custom color matching for brand recognition, safe identification and aesthetics in medical device applications. Since pigment requirements are ever changing, LifeSciences pays close attention to ensure that colorants meet applicable regulatory requirements.

Along with color matching, LLS also offers radiopaque materials for X-ray identification and proper device positioning; critical for patient safety and comfort. Pellethane and Isoplast compounds with barium sulfate and tungsten are now both available from LLS.

Pellethane thermoplastic polyurethane is available as aromatic polyethers or polyesters and are known for their flexibility and wide range of hardness. Pellethane TPUs are excellent for a variety of medical applications including tubing, catheters and other short-term uses.

Isoplast engineered thermoplastic polyurethanes are designed for rigid polymer requirements due to their high tensile strength and impact resistance. Isoplast medical polymers may be used to replace polycarbonate where stress cracking is an issue or coloring is difficult. Isoplast is ideal for applications needing an impact resistance-based polymer.

This new capability is made possible through a partnership with trusted custom medical plastics compounder, Compounding Solutions. Compounding Solutions is committed to manufacturing specialty plastics compounds and concentrates of the highest quality in order to satisfy requirements of the medical device industry.

© 2017 David Mazor

Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.